An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years.

Trial Profile

An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Therapeutic Use
  • Sponsors Ception Therapeutics
  • Most Recent Events

    • 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 May 2011 Results presented at the Digestive Disease Week 2011.
    • 30 Sep 2009 Actual patient number (226) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top